Cargando…
Massive adrenal incidentalomas and late diagnosis of congenital adrenal hyperplasia in prostate cancer
In a 61-year-old Caucasian male with prostate cancer, leuprolide and bicalutamide failed to suppress the androgens. He presented to endocrinology with persistently normal testosterone and incidental massive (up to 18 cm) bilateral adrenal myelolipomas on CT scan. Blood test did not reveal metanephri...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5670323/ https://www.ncbi.nlm.nih.gov/pubmed/29118987 http://dx.doi.org/10.1530/EDM-17-0108 |
_version_ | 1783276000761610240 |
---|---|
author | Feng, Xin Kline, Gregory |
author_facet | Feng, Xin Kline, Gregory |
author_sort | Feng, Xin |
collection | PubMed |
description | In a 61-year-old Caucasian male with prostate cancer, leuprolide and bicalutamide failed to suppress the androgens. He presented to endocrinology with persistently normal testosterone and incidental massive (up to 18 cm) bilateral adrenal myelolipomas on CT scan. Blood test did not reveal metanephrine excess. The patient was noted to have short stature (151 cm) and primary infertility. Elementary school photographs demonstrated precocious puberty. Physical examination revealed palpable abdominal (adrenal) masses. Abiraterone and glucocorticoid treatment was commenced with excellent suppression of testosterone. Genetic testing revealed a mutation in CYP21A2 confirming 21-hydroxylase-deficient congenital adrenal hyperplasia (CAH). Association of large myelolipomas with CAH has been reported in the literature. Our case highlights the importance of considering CAH in patients with non-suppressed testosterone despite androgen deprivation therapy. Large myelolipomas should raise the suspicion of congenital adrenal hyperplasia. LEARNING POINTS: Adrenal myelolipomas are rare benign lesions that are more common in patients with longstanding untreated congenital adrenal hyperplasia thought to be due to ACTH stimulation. Consider undiagnosed congenital adrenal hyperplasia in patients with adrenal myelolipoma. Glucocorticoid replacement may be an efficacious treatment for patients with prostate cancer and CAH. Abiraterone therapy has a risk of adrenal crisis if glucocorticoids are not replaced. |
format | Online Article Text |
id | pubmed-5670323 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Bioscientifica Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-56703232017-11-08 Massive adrenal incidentalomas and late diagnosis of congenital adrenal hyperplasia in prostate cancer Feng, Xin Kline, Gregory Endocrinol Diabetes Metab Case Rep Unique/Unexpected Symptoms or Presentations of a Disease In a 61-year-old Caucasian male with prostate cancer, leuprolide and bicalutamide failed to suppress the androgens. He presented to endocrinology with persistently normal testosterone and incidental massive (up to 18 cm) bilateral adrenal myelolipomas on CT scan. Blood test did not reveal metanephrine excess. The patient was noted to have short stature (151 cm) and primary infertility. Elementary school photographs demonstrated precocious puberty. Physical examination revealed palpable abdominal (adrenal) masses. Abiraterone and glucocorticoid treatment was commenced with excellent suppression of testosterone. Genetic testing revealed a mutation in CYP21A2 confirming 21-hydroxylase-deficient congenital adrenal hyperplasia (CAH). Association of large myelolipomas with CAH has been reported in the literature. Our case highlights the importance of considering CAH in patients with non-suppressed testosterone despite androgen deprivation therapy. Large myelolipomas should raise the suspicion of congenital adrenal hyperplasia. LEARNING POINTS: Adrenal myelolipomas are rare benign lesions that are more common in patients with longstanding untreated congenital adrenal hyperplasia thought to be due to ACTH stimulation. Consider undiagnosed congenital adrenal hyperplasia in patients with adrenal myelolipoma. Glucocorticoid replacement may be an efficacious treatment for patients with prostate cancer and CAH. Abiraterone therapy has a risk of adrenal crisis if glucocorticoids are not replaced. Bioscientifica Ltd 2017-10-28 /pmc/articles/PMC5670323/ /pubmed/29118987 http://dx.doi.org/10.1530/EDM-17-0108 Text en © 2017 The authors http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en_GB This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en_GB) . |
spellingShingle | Unique/Unexpected Symptoms or Presentations of a Disease Feng, Xin Kline, Gregory Massive adrenal incidentalomas and late diagnosis of congenital adrenal hyperplasia in prostate cancer |
title | Massive adrenal incidentalomas and late diagnosis of congenital adrenal hyperplasia in prostate cancer |
title_full | Massive adrenal incidentalomas and late diagnosis of congenital adrenal hyperplasia in prostate cancer |
title_fullStr | Massive adrenal incidentalomas and late diagnosis of congenital adrenal hyperplasia in prostate cancer |
title_full_unstemmed | Massive adrenal incidentalomas and late diagnosis of congenital adrenal hyperplasia in prostate cancer |
title_short | Massive adrenal incidentalomas and late diagnosis of congenital adrenal hyperplasia in prostate cancer |
title_sort | massive adrenal incidentalomas and late diagnosis of congenital adrenal hyperplasia in prostate cancer |
topic | Unique/Unexpected Symptoms or Presentations of a Disease |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5670323/ https://www.ncbi.nlm.nih.gov/pubmed/29118987 http://dx.doi.org/10.1530/EDM-17-0108 |
work_keys_str_mv | AT fengxin massiveadrenalincidentalomasandlatediagnosisofcongenitaladrenalhyperplasiainprostatecancer AT klinegregory massiveadrenalincidentalomasandlatediagnosisofcongenitaladrenalhyperplasiainprostatecancer |